Drugs / JNJ-67835989
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04844411 | Apr 2021 → May 2022 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-67835989 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04844411 ↗ |
| Route | Oral | “JNJ-67835989 will be administered orally.” NCT04844411 ↗ |